Paper27367478
'Acute myeloid leukemia: a comprehensive review and 2016 update'.
De Kouchkovsky I and 1 other. Blood Cancer J, 2016. Cited by 999 papers, by iCite.
Cite this record
ConductScience Library. 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Papers, record 27367478. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27367478
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Humans | |
| Immunotherapy | |
| Molecular Targeted Therapy | |
| Prognosis |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT04392310 | Outcomes of Acute Myeloid Leukemia Patients | Background | ClinicalTrials.gov | |
| NCT04708444 | Prognostic Value of CD318 in AML at Assiut University Hospital. | Background | ClinicalTrials.gov | |
| NCT06483906 | Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. | Background | ClinicalTrials.gov |
References114
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25993000 | High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials. | PLoS One | 2015 | https://conductscience.org/library/papers/25993000 | PubMed |
| 2 | 16921041 | Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16921041 | PubMed |
| 3 | 20952518 | Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. | Haematologica | 2011 | https://conductscience.org/library/papers/20952518 | PubMed |
| 4 | 22039260 | Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. | Blood | 2012 | https://conductscience.org/library/papers/22039260 | PubMed |
| 5 | 25887778 | Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. | Blood | 2015 | https://conductscience.org/library/papers/25887778 | PubMed |
| 6 | 8874180 | A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. | Blood | 1996 | https://conductscience.org/library/papers/8874180 | PubMed |
| 7 | 24726781 | Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. | Leuk Res | 2014 | https://conductscience.org/library/papers/24726781 | PubMed |
| 8 | 10023702 | Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. | Cancer | 1999 | https://conductscience.org/library/papers/10023702 | PubMed |
| 9 | 18064533 | Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. | Cancer Causes Control | 2008 | https://conductscience.org/library/papers/18064533 | PubMed |
| 10 | 17213292 | Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? | Blood | 2007 | https://conductscience.org/library/papers/17213292 | PubMed |
| 11 | 2045861 | Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. | J Clin Oncol | 1991 | https://conductscience.org/library/papers/2045861 | PubMed |
| 12 | 24623852 | Crenolanib is a selective type I pan-FLT3 inhibitor. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/24623852 | PubMed |
| 13 | 25449688 | Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. | Leuk Res | 2014 | https://conductscience.org/library/papers/25449688 | PubMed |
| 14 | 25721896 | CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. | Leukemia | 2015 | https://conductscience.org/library/papers/25721896 | PubMed |
| 15 | 20212254 | Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20212254 | PubMed |
| 16 | 16051734 | Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. | Blood | 2005 | https://conductscience.org/library/papers/16051734 | PubMed |
| 17 | 23558173 | Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. | Science | 2013 | https://conductscience.org/library/papers/23558173 | PubMed |
| 18 | 26811524 | Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/26811524 | PubMed |
| 19 | 2475589 | On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2475589 | PubMed |
| 20 | 23786647 | Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. | Br J Haematol | 2013 | https://conductscience.org/library/papers/23786647 | PubMed |
Cited by718
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 999 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42977970 | FGFBPs in health and tumors: emerging prognostic biomarkers and therapeutic implications. | Biomark Res | 2026 | https://conductscience.org/library/papers/42977970 | PubMed |
| 42919186 | Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia. | BMC Geriatr | 2026 | https://conductscience.org/library/papers/42919186 | PubMed |
| 42881859 | Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models. | J Clin Med | 2026 | https://conductscience.org/library/papers/42881859 | PubMed |
| 42814135 | Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant Leukemia. | Blood Cancer Discov | 2026 | https://conductscience.org/library/papers/42814135 | PubMed |
| 42807630 | Hereditary Predisposition to Acute Myeloid Leukemia: A Novel Germline CEBPA Mutation in a Multigenerational Family. | Case Rep Hematol | 2026 | https://conductscience.org/library/papers/42807630 | PubMed |
| 42688360 | More precise risk stratification for de novo acute myeloid leukemia with double-mutation CEBPA. | Ther Adv Hematol | 2026 | https://conductscience.org/library/papers/42688360 | PubMed |
| 42589161 | Molecular Docking and Simulation-Based Exploration of Niclosamide as a Potential Inhibitor of the p62 ZZ Domain. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/42589161 | PubMed |
| 42541488 | Sodium Overload-Related Molecular Subtypes and a Four-Gene Prognostic Signature Predict Survival, Immune Landscape, and Therapeutic Response in Acute Myeloid Leukemia. | Mol Carcinog | 2026 | https://conductscience.org/library/papers/42541488 | PubMed |
| 42507679 | A systems biology approach to find representative genes in Acute Myeloid Leukemia. | PLoS One | 2026 | https://conductscience.org/library/papers/42507679 | PubMed |
| 42499707 | RSK signaling in myeloid malignancies: biology, disease dependency, and therapeutic targeting. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42499707 | PubMed |
| 42438298 | DHX15 affects AML1-ETO9a splicing together with HNRNPL, RBM33 in AML1-ETO-positive acute myeloid leukaemia. | Br J Haematol | 2026 | https://conductscience.org/library/papers/42438298 | PubMed |
| 42434847 | QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. | Future Oncol | 2026 | https://conductscience.org/library/papers/42434847 | PubMed |
| 42412348 | Incidence, etiology, and predictors of early mortality after induction chemotherapy for aml in a middle-income country. | Int J Hematol | 2026 | https://conductscience.org/library/papers/42412348 | PubMed |
| 42388349 | Identification of long non-coding RNAs involved in leukemogenesis and venetoclax response in acute myeloid leukemia through functional CRISPR-dCas9 interference screens. | Noncoding RNA Res | 2026 | https://conductscience.org/library/papers/42388349 | PubMed |
| 42350371 | Mitochondrial integrated stress response activation creates a therapeutic vulnerability to MCL-1 inhibition in acute myeloid leukemia. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42350371 | PubMed |
| 42279389 | Myeloid Malignancies Beyond the Cell: Targeting the Tumour Microenvironment with Next-Generation Immunotherapies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279389 | PubMed |
| 42265630 | Upregulation of NFS1 and downregulation of GSDMD as prognostic biomarkers in acute myeloid leukemia: implications for diagnosis and therapeutic strategies. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42265630 | PubMed |
| 42243832 | Exploring CAR cell therapies beyond CAR-T for myeloid malignancies. | J Biomed Sci | 2026 | https://conductscience.org/library/papers/42243832 | PubMed |
| 42095623 | Arginine deprivation induces prolonged autophagy activation and ROS-dependent cell death in glioblastoma multiforme. | CNS Oncol | 2026 | https://conductscience.org/library/papers/42095623 | PubMed |
| 42087483 | Clinical Characteristics, Gene Mutation Profiles and Prognosis of Patients With Acute Myeloid Leukemia Carrying PHF6 Mutations. | Cancer Med | 2026 | https://conductscience.org/library/papers/42087483 | PubMed |
Genes36
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27367478
GET https://conductscience.org/api/papers/v1/27367478/references?page=2